β blockers for the treatment of primary hypertension [6]

Lancet

Volumn 367, Issue 9506, 2006, Pages 208-

  Khan, Nadia ^a,b   McAlister, Finlay A ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ARTERY COMPLIANCE; CARDIOVASCULAR RISK; CLINICAL TRIAL; HIGH OUTPUT HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY FAILURE; LETTER; META ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; STROKE; SYSTEMATIC REVIEW; VASCULAR RESISTANCE;

EID: 30844470436     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68027-6     Document Type: Letter

References (5)

1. LH Lindholm, B Carlberg, O Samuelsson Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis Lancet 366 2005 1545 1553
2. DG Beevers The end of β blockers for uncomplicated hypertension? Lancet 366 2005 1510 1512
3. L Hansson, LH Lindholm, L Niskanen Effect of angiotensin-converting- enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial Lancet 353 1999 611 616
4. Veterans Administration Cooperative Study Group on Antihypertensive Agents Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension - II, results of long-term therapy JAMA 248 1982 2004 2011
5. JT Wright Jr, G Bakris, T Greene for the African American Study of Kidney Disease and Hypertension Study Group Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial JAMA 288 2002 2421 2431